China Pharma Holdings (CPHI) Income towards Parent Company (2010 - 2026)

China Pharma Holdings (CPHI) has reported Income towards Parent Company for 17 consecutive years, with -$1.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Income towards Parent Company fell 175.97% year-over-year to -$1.5 million; the trailing twelve-month figure through Jun 2026 stood at -$4.5 million (down 22.39% YoY), and the FY2025 full-year result was -$2.4 million, up 32.7% from the prior year.
• Income towards Parent Company eased to -$1.5 million in Q2 2026 per CPHI's latest filing, from -$1.1 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$475976.0 in Q1 2023 and bottomed at -$1.5 million in Q2 2026.
• Historically, Income towards Parent Company has averaged -$976491.7 across 5 years, with a median of -$992691.0 in 2022.
• The sharpest annual moves came in 2025 and 2026: Income towards Parent Company surged 63.26% in 2025, then sank 175.97% in 2026.
• Over 5 years, Income towards Parent Company stood at -$1.3 million in 2022, then increased by 2.53% to -$1.2 million in 2023, then gained by 0.63% to -$1.2 million in 2024, then rose by 0.19% to -$1.2 million in 2025, then retreated by 19.31% to -$1.5 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$1.5 million, -$1.1 million, and -$1.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.